Warning: Trying to access array offset on false in /usr/www/users/medzip/Prod/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 55

Warning: Trying to access array offset on false in /usr/www/users/medzip/Prod/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 55

Warning: Trying to access array offset on false in /usr/www/users/medzip/Prod/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 55

Hematologie

Het laatste nieuws binnen hematologie

Warning: Trying to access array offset on false in /usr/www/users/medzip/Prod/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 239

Warning: Trying to access array offset on false in /usr/www/users/medzip/Prod/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 239

Warning: Trying to access array offset on false in /usr/www/users/medzip/Prod/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 239

Warning: Trying to access array offset on false in /usr/www/users/medzip/Prod/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 446

Warning: Trying to access array offset on false in /usr/www/users/medzip/Prod/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 446

Warning: Trying to access array offset on false in /usr/www/users/medzip/Prod/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 446
Bloedtransfusie
Terugblik op Hematologie in Beweging 2026
Een dag vol nieuwe inzichten, inspirerende discussies en praktische handvatten. Op 9 oktober kwamen hematologische zorgverleners samen in Utrecht voor het symposium Hematologie in Beweging 2026. Een dag waarop niet alleen de nieuwste medisch-inhoudelijke ontwikkelingen centraal stonden, maar vooral ook de vraag: hoe kunnen we de zorg voor onze patiënten steeds beter, persoonlijker en passender […]

Aanbevolen

Aritmie
Eén pictogrammenset voor begrijpelijkere medicijninformatie
Waar kom je de pictogrammen tegen?  Medicijngebruikers komen de pictogrammen straks tegen in de informatie die de apotheker geeft, bijvoorbeeld wanne...
Aritmie
Ambulancezorg, elke dag anders, elke dag zorg: regie
Op locatie Er is niet alleen sprake van minder kracht (parese), maar van volledige uitval links (paralyse). Ook is mevrouw niet meer tot spreken in st...

Warning: Undefined variable $card_class in /usr/www/users/medzip/Prod/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 437

Warning: Undefined variable $card_class in /usr/www/users/medzip/Prod/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 437

Warning: Undefined variable $card_class in /usr/www/users/medzip/Prod/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 437

Warning: Undefined variable $card_class in /usr/www/users/medzip/Prod/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 437

Warning: Undefined variable $card_class in /usr/www/users/medzip/Prod/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 437

Warning: Undefined variable $card_class in /usr/www/users/medzip/Prod/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 437

Warning: Undefined variable $card_class in /usr/www/users/medzip/Prod/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 437

Warning: Undefined variable $card_class in /usr/www/users/medzip/Prod/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 437

Hematologie nieuws

Het laatste nieuws binnen hematologie

Bloedtransfusie

HLA?antibody testing female donors with a pregnancy history augments the low titer group O whole blood supply
Low titer group O whole blood (LTOWB) use across the United States is increasing. This simulation calculated the number of female donors who would qua...
How do we build a transfusion safety program during challenging times?
onlinelibrary.wiley.com
The SARS-CoV-2 pandemic led to systemic shortages in the blood supply that highlighted the importance of blood stewardship and optimal blood utilizati...
A retrospective evaluation of responsiveness to platelets in plasma and pathogen?reduced platelets in platelet additive solution at a single institution
onlinelibrary.wiley.com
Studies suggest that recipients of pathogen reduced (PR) platelets in platelet additive solution (PAS) experience inferior increments when compared to...
Toon meer

Hemostase/trombose

Maligne hematologie

Real-world access and barriers to CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: a population-based study
astctjournal.org
Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoid malignancy that is often curable by first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or similar chemoimmunotherapy.1,2 However, up to 30-40% of patients do not achieve durable remission with first-line treatment, and outcomes of relapsed or refractory (R/R) disease were historically poor, with a median survival around 5-6 months and 5-year survival rates of <20-30%.3-5 The emergence of chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment landscape for R/R DLBCL, achieving durable remissions in approximately 40-50% of treated patients.
Real-world access and barriers to CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: a population-based study
astctjournal.org
Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoid malignancy that is often curable by first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or similar chemoimmunotherapy.1,2 However, up to 30-40% of patients do not achieve durable remission with first-line treatment, and outcomes of relapsed or refractory (R/R) disease were historically poor, with a median survival around 5-6 months and 5-year survival rates of <20-30%.3-5 The emergence of chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment landscape for R/R DLBCL, achieving durable remissions in approximately 40-50% of treated patients.
Daratumumab, Bortezomib, Lenalidomide and Dexamethasone, Upfront Autologous Transplant and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma
astctjournal.org
The therapeutic landscape of multiple myeloma has changed rapidly over the past several years. The prospective phase-II GRIFFIN and phase-III PERSEUS trials showed improved depth of response and progression-free survival (PFS) with a quadruplet induction regimen incorporating the anti-CD38 monoclonal antibody daratumumab, in combination with bortezomib, lenalidomide (Len), and dexamethasone (D-VRd), compared with the triplet regimen VRd, in transplant-eligible newly diagnosed multiple myeloma (NDMM) 1,2.
Toon meer